Results of the ONTARGET and TRANSCEND studies: an update and discussion

References

• WagenaarLJVoorsAABuikemaHvan GilstWHAngiotensin receptors in the cardiovascular systemCan J Cardiol20021813311339
   Google Scholar
• YusufSTeoKKPogueJDyalLCoplandISchumacherHDagenaisGSleightPAndersonCTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. Published on-line 29 August 2008, DOI:10.1016/S0140-6736(08)61242–1248
   Google Scholar
• DzauVJMechanism of protective effects of ACE inhibition on coronary artery diseaseEur Heart J199819Suppl JJ2J69796834
   PubMedGoogle Scholar
• BrownNJKumarSPainterCAVaughanDEACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over timeHypertension200240685986512468570
   PubMed Web of Science ®Google Scholar
• KimMPZhouMWahlLMAngiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: Implications for atherosclerotic plaque ruptureJ Leukoc Biol20057819520115817699
   PubMed Web of Science ®Google Scholar
• The SOLVD investigatorsEffect of enalapril on survival in patients with reduced ejection fraction and congestive heart failureN Engl J Med19913252933022057034
   PubMed Web of Science ®Google Scholar
• PfefferMABraunwaldEMoyeLAEffect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE InvestigatorsN Engl J Med1992327106696771386652
   PubMed Web of Science ®Google Scholar
• RutherfordJDPfefferMAMoyeLAEffects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE InvestigatorsCirculation1994904173117387923656
   PubMed Web of Science ®Google Scholar
• YusufSSleightPPogueJBoschJDaviesRDagenaisGEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators (see comments)N Engl J Med2000342314515310639539
   PubMed Web of Science ®Google Scholar
• The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease InvestigatorsEfficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised double-blind, placebo-controlled, multicentre trial (the EUROPA study)Lancet200336278278813678872
   PubMed Web of Science ®Google Scholar
• The PEACE InvestigatorsAngiotensin-Converting–Enzyme Inhibitionin Stable Coronary Artery DiseaseN Engl J Med20043512058206815531767
   PubMed Web of Science ®Google Scholar
• DagenaisGRPogueJFoxKSimoonsMLYusufSAngiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trialsLancet2006368953558158816905022
   PubMed Web of Science ®Google Scholar
• DanchinNCucheratMThuillezCDurandEKadriZStegPGAngiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trialsArch Intern Med2006166778779616606817
   PubMedGoogle Scholar
• GrangerCBErtlGKuchJRandomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitorsAm Heart J2000139460961710740141
   PubMed Web of Science ®Google Scholar
• GrangerCBMcMurrayJJYusufSEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialLancet2003362938677277613678870
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEdeZEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med20013451286186911565518
   PubMed Web of Science ®Google Scholar
• ParvingHHLehnertHBrochnerMGomisRAndersenSArnerPThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med20013451287087811565519
   PubMed Web of Science ®Google Scholar
• PfefferMASwedbergKGrangerCBEffects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeLancet2003362938675976613678868
   PubMed Web of Science ®Google Scholar
• McMurrayJJOstergrenJSwedbergKEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialLancet2003362938676777113678869
   PubMed Web of Science ®Google Scholar
• DemersCMcMurrayJJSvedbergKImpact of candesartan in preventing myocardial infarction: results of the Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity (CHARM) ProgrammeCirculation1102004Suppl IIIIII514
   Google Scholar
• DahlofBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet20023599311995100311937178
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet20043632022203115207952
   PubMed Web of Science ®Google Scholar
• FlatherMDYusufSKoberLLong-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group (see comments)Lancet200035592151575158110821360
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003349201893190614610160
   PubMed Web of Science ®Google Scholar
• StraussMHHallASAngiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradoxCirculation2006114883885416923768
   PubMed Web of Science ®Google Scholar
• TeoKKBurtonJRBullerCPlanteSYokoyamaSMontagueTJRationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT InvestigatorsCan J Cardiol19971365915999215232
   PubMed Web of Science ®Google Scholar
• MannJFSchmiederREMcQueenMRenal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trialLancet2008372963854755318707986
   PubMed Web of Science ®Google Scholar
• YusufSDienerHCSaccoRLTelmisartan to prevent recurrent stroke and cardiovascular eventsN Engl J Med2008
   Web of Science ®Google Scholar
• NakaoNYoshimuraAMoritaHTakadaMKayanoTIdeuraTCombination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trialLancet2003361935211712412531578
   PubMed Web of Science ®Google Scholar
• KunzRWolbersMGlassTMannJThe COOPERATE trial: a letter of concernLancet20083711575157618468534
   PubMed Web of Science ®Google Scholar
• HOPE/HOPE-TOO Study InvestigatorsResults of the HOPE study extension. long-term effects of ramipril on cardiovascular events and on diabetesCirculation20051121339134616129815
   PubMed Web of Science ®Google Scholar
• HallASMurrayGDBallSGFollow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) StudyLancet1997349149314979167457
   PubMed Web of Science ®Google Scholar
• Canadian Diabetes Association Clinical Practice Guidelines Expert CommitteeCanadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in CanadaCan J Diabetes200832suppl 1S1S201
   Google Scholar